ABN Amro Investment Solutions Buys 3,234 Shares of IQVIA Holdings Inc. $IQV

ABN Amro Investment Solutions boosted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 51.1% in the 1st quarter, HoldingsChannel reports. The firm owned 9,557 shares of the medical research company’s stock after buying an additional 3,234 shares during the period. ABN Amro Investment Solutions’ holdings in IQVIA were worth $1,630,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Oslo Pensjonsforsikring AS bought a new stake in shares of IQVIA during the first quarter valued at approximately $347,000. Andra AP fonden raised its holdings in IQVIA by 320.1% during the 1st quarter. Andra AP fonden now owns 121,405 shares of the medical research company’s stock worth $20,704,000 after purchasing an additional 92,505 shares during the last quarter. Leith Wheeler Investment Counsel Ltd. acquired a new position in IQVIA during the 1st quarter valued at about $285,000. Dimensional Fund Advisors LP grew its position in shares of IQVIA by 4.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,657,696 shares of the medical research company’s stock worth $282,657,000 after buying an additional 66,643 shares during the period. Finally, Balefire LLC raised its stake in shares of IQVIA by 11.9% during the first quarter. Balefire LLC now owns 16,467 shares of the medical research company’s stock worth $2,808,000 after buying an additional 1,749 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Up 0.4%

IQV opened at $208.22 on Friday. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $247.04. The stock has a market capitalization of $34.75 billion, a price-to-earnings ratio of 25.80, a P/E/G ratio of 1.86 and a beta of 1.20. The company has a 50-day simple moving average of $188.23 and a 200 day simple moving average of $187.38.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. During the same period in the previous year, the business earned $2.70 EPS. The business’s quarterly revenue was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA announced that its board has initiated a share repurchase plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of analyst reports. Weiss Ratings raised IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. Morgan Stanley reissued an “equal weight” rating and issued a $200.00 target price (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Evercore reaffirmed an “outperform” rating and issued a $185.00 price target on shares of IQVIA in a research note on Wednesday, April 8th. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on shares of IQVIA in a research note on Thursday, July 9th. Finally, Mizuho lifted their price objective on IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Thirteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $225.71.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.